Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06870019 · ClinicalTrials.gov registry record · NA
Hepatitis C Tracker Study
A NA study of Hepatitis C Virus Infection, sponsored by University of Southern California.
- Recruiting
- Registry status
- NA
- Development phase
- 124
- Enrollment target
- 2
- Study locations
NCT06870019 is a NA study of Hepatitis C Virus Infection that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 124 participants, below the 178-participant average among 5 other Hepatitis C Virus Infection trials with a reported enrollment target (30% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06870019, a NA study of Hepatitis C Virus Infection, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to determine if GPS tracking can enhance adherence to hepatitis C treatment among patients diagnosed with hepatitis C infection who are also experiencing unsheltered homelessness and receiving street medicine. Research will compare medication adherence among participants randomly assigned to receive standard medical care for Hepatitis C versus the standard medical care for Hepatitis C along with GPS tracking assistance.
Conditions Studied
Interventions
- BEHAVIORAL GPS tracker device
Study Locations (2)
California
- USC Street Medicine - Alhambra
- Ventura County Medical Center - Ventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2025-08-08 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06870019
The ClinicalTrials.gov registry entry for NCT06870019 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 5 other Hepatitis C Virus Infection trials with a reported enrollment target (30% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C Virus Infection appearing as the primary indexed condition, and to 1 intervention - of which GPS tracker device is the first listed.
NCT06870019 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06870019 about?
NCT06870019 is a clinical study titled "Hepatitis C Tracker Study". The goal of this study is to determine if GPS tracking can enhance adherence to hepatitis C treatment among patients diagnosed with hepatitis C infection who are also experiencing unsheltered homelessness and receiving street medicine. Research will compare medication adherence among participants ra...
What is the current status of trial NCT06870019?
This trial is currently recruiting. It is a NA study. The enrollment target is 124 participants. The study started on 2025-08-08. Estimated completion is 2027-12-31.
What conditions does trial NCT06870019 study?
This clinical trial studies the following conditions: Hepatitis C Virus Infection.
What interventions are being tested in trial NCT06870019?
The interventions under investigation include: GPS tracker device (BEHAVIORAL).
Who is sponsoring clinical trial NCT06870019?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06870019 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
COMPLETED · Phase 3
-
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
COMPLETED · Phase 3
-
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
COMPLETED · Phase 2
-
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
COMPLETED · Phase 2
-
Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.